Skip to main content

Table 2 Univariate logistic regression analysis of clinicopathologic factors and effect of neoadjuvant chemotherapy

From: Predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer using multiparametric MRI

Variable Univariate analysis
OR 95% CI P value
Patient age (years)    
 < 50 0.450 0.116–1.751 0.249
 ≥ 50 Ref   
Histological type    
 Invasive 1.636 0.135–19.808 0.699
 Other Ref   
Histologic grade*    
 1–2 0.156 0.018–1.339 0.090
 3 Ref   
Clinical stage*    
 I–II 9.667 2.145–43.563 0.003
 III Ref   
T stage*    
 T1–T2 0.119 0.027–0.530 0.005
 T3–T4 Ref   
N stage*    
 N0 0.943 0.089–10.010 0.961
 N1–3 Ref   
Lymph node size*    
 ≤ 1.0 cm 0.982 0.263–3.662 0.979
 > 2.0 cm Ref   
NAC regimen    
 EC 1.333 0.196–9.083 0.769
 EC-T(H) 1.333 0.220–8.099 0.755
 TEC or other Ref   
NAC cycle    
 1–4 1.560 0.359–6.775 0.553
 5–8 Ref   
CEA level*    
 Normal 0.600 0.063–5.709 0.657
 Abnormal Ref   
CA125 level*    
 Normal 1.061 0.100–11.260 0.961
 Abnormal Ref   
CA153 level*    
 Normal 2.333 0.341–15.952 0.388
 Abnormal Ref   
Breast cancer subtype    
 TNBC Ref   
 Her-2 positive 0.500 0.070–3.550 0.488
 Luminal A/B 0.545 0.121–2.449 0.429
 Ki-67 status    
 ≤ 20% 2.600 0.495–13.668 0.259
 > 20% Ref   
  1. NAC neoadjuvant chemotherapy, TNBC triple-negative breast cancer, EC epirubicin plus cyclophosphamide, TH docetaxel plus Herceptin, TEC docetaxel,epirubicin plus cyclophosphamide
  2. *Data are measured at baseline. The data of patient age and tumor size are mean ± standard deviation